In Vitro Activities of Isepamicin, Other Aminoglycosides, and Capreomycin against Clinical Isolates of Rapidly Growing Mycobacteria in Taiwan-Reference-Cited by-同舟云学术

In Vitro Activities of Isepamicin, Other Aminoglycosides, and Capreomycin against Clinical Isolates of Rapidly Growing Mycobacteria in Taiwan

Published:2007-05 Issue:5 Volume:51 Page:1849-1851
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Shen Gwan-Han¹²,Wu Bo-Da¹,Wu Kun-Ming³,Chen Jiann-Hwa²

Affiliation:

1. Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China

2. Institute of Molecular Biology, National Chung Hsing University, Taichung, Taiwan, Republic of China

3. Rui-Fu-Shi Medical Laboratory, Taichung, Taiwan, Republic of China

Abstract

ABSTRACT The in vitro activities of isepamicin against 117 Mycobacteria abscessus , 48 Mycobacterium fortuitum , and 20 Mycobacterium chelonae isolates were evaluated by a microdilution test. Isepamicin MIC 90 s were ≤16 μg/ml for the three species. Isepamicin was as active as amikacin and kanamycin and more active than tobramycin, capreomycin, gentamicin, and streptomycin.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01551-06

Reference18 articles.

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med.156:S1-S25.

2. Barrett, M. S., R. N. Jones, M. E. Erwin, and F. P. Koontz. 1992. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum. Diagn. Microbiol. Infect. Dis.15:169-171.

3. Blum, D. 1995. An overview of the safety of isepamicin in adults. J. Chemother.7(Suppl. 2):87-93.

4. Cheng, N. C., P. R. Hsueh, Y. C. Liu, J. M. Shyr, W. K. Huang, L. J. Teng, and C. Y. Liu. 2005. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb. Drug Resist.11:330-341.

5. Dalovisio, J. R., G. A. Pankey, R. J. Wallace, and D. B. Jones. 1981. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev. Infect. Dis.3:1068-1074.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

2. Mycobacterium abscessus drug discovery using machine learning;Tuberculosis;2022-01

3. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates;Journal of Microbiology, Immunology and Infection;2018-10

4. In VitroAntimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran;Microbial Drug Resistance;2016-03

5. Rapidly growing mycobacteria in Singapore, 2006–2011;Clinical Microbiology and Infection;2015-03